Authors: Stephan R Vavricka Alain M Schoepfer Michael Scharl Gerhard Rogler
Publish Date: 2014/02/15
Volume: 74, Issue: 3, Pages: 313-324
Abstract
The incidence and prevalence of Crohn’s disease are increasing particularly in the Western world and Asia Corticosteroids have been used for decades to treat active Crohn’s disease and remain the mainstay in the management of moderatetosevere relapses in Crohn’s disease The use of corticosteroids despite their efficacy may be associated with several drawbacks This review article provides a comprehensive account of the role of corticosteroids in inducing remission in adult patients with Crohn’s disease including aspects such as approaches to corticosteroid sparing and to minimize the risk of corticosteroid dependency as well as the role of newer corticosteroids such as budesonide in reducing systemic adverse effectsThis research was supported by grants from the Swiss National Science Foundation SNSF to SRV Grant No 320000114009/3 and 32473B 135694/1 to GR Grant No 310030120312 to AS Grant No 32003B 135665/1 to MS Grant No 314730146204 to the Swiss IBD Cohort Grant No 3347CO108792 and the Center for Integrative Human Physiology of the University of Zurich to SRV MS and GR
Keywords: